Premium
Enhancement of Influenza Vaccine ‐ Induced Antibody Titers with Active Hexose Correlated Compound (AHCC)
Author(s) -
Wang Reginald,
Kudo Shotaro
Publication year - 2015
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.29.1_supplement.lb327
Subject(s) - antibody titer , placebo , medicine , vaccination , titer , antibody , immunology , influenza vaccine , gastroenterology , pathology , alternative medicine
AHCC® is a mushroom‐derived polysaccharide that has been shown to increase markers of immune activity including CD4, CD8 and NK cell numbers, TNF production and antibody responses to selected vaccines. This randomized, double‐blinded, placebo‐controlled trial was designed to further investigate the potential for enhancement of influenza antibody formation following vaccination and to explore the efficacy of AHCC in subjects who had a routine seasonal influenza vaccination. Prior to vaccination, Influenza A and B antibody titers in blood were analyzed (baseline). Twenty‐nine subjects were randomly administered 1 g of AHCC (2 capsules) or placebo daily for 4 weeks (n=15 for placebo; n=14 for AHCC). Antibody titers were analyzed again at 4 weeks (follow up). Titer increase for either Influenza Type A or B Antibody from baseline to follow up was significantly increased in 60% of placebo‐treated group and 85.7% of AHCC‐treated group (1 gram dosage). These results suggest that 1 gram AHCC can increase influenza vaccine efficacy of Type A and B.